Drug
Ramucirumab
Ramucirumab: highest development phase Phase 2, developed by Eli Lilly. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ramucirumab NCT02443883 | Phase 2 | Gastric Adenocarcinoma |
| Ramucirumab NCT02359058 | Phase 1 | Stomach Neoplasms |
Latest
No recent events.
Follow Ramucirumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.